By modifying bile acid metabolism and FXR/TGR5 signaling, gut flora could therefore contribute indirectly to the pathogenesis of metabolic syndrome, and manipulation of its composition can be a promising novel drug target for the treatment of the obesity-associated diseases. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.